Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Dow
Cantor Fitzgerald
Chubb
Accenture
US Army
Harvard Business School
AstraZeneca
Federal Trade Commission

Generated: September 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,597,331

« Back to Dashboard

Title:Therapeutic compositions containing macitentan
Abstract: The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof. ##STR00001##
Inventor(s): Clozel; Martine (Binningen, CH)
Assignee: ACTELION PHARMACEUTICALS LTD. (Allschwil, CH)
Filing Date:Oct 02, 2015
Application Number:14/873,787
Claims:1. A method for the treatment of a disease selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction, angina pectoris and pulmonary fibrosis, comprising administering macitentan, in free or pharmaceutically acceptable salt form, in combination with an effective amount of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof, wherein the compound having prostacyclin receptor (IP) agonist properties is selected from iloprost and its pharmaceutically acceptable salts.

2. The method according to claim 1, wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered simultaneously, separately or over a period of time.

3. The method according to claim 2, wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered simultaneously.

4. The method according to claim 2, wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered separately.

5. The method according to claim 2, wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered over a period of time.

6. The method according to claim 1, wherein the disease is pulmonary hypertension.

7. The method according to claim 1, wherein the disease is pulmonary arterial hypertension.

8. The method according to claim 7, wherein the macitentan is in free form.

9. A method for the treatment of pulmonary arterial hypertension comprising administering an effective amount of macitentan in free or pharmaceutically acceptable salt form, in combination with iloprost, in free or pharmaceutically acceptable salt form.

10. The method according to claim 9, wherein the macitentan and the iloprost are administered simultaneously.

11. The method according to claim 9, wherein the macitentan and the iloprost are administered separately.

12. The method according to claim 9, wherein the macitentan and the iloprost are administered over a period of time.

13. The method according to claim 9, wherein the macitentan is administered once a day.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Dow
Healthtrust
Mallinckrodt
Moodys
US Army
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.